Abstract
The calcitonin gene-related peptide (CGRP) family of peptides includes CGRP itself, calcitonin (CT), adrenomedullin (AM), and amylin (AMY). The peptides share several aspects of G-protein-coupled receptors. The 7-transmembrane (7TM) part of the receptor has either the calcitonin receptor like-receptor (CLR) or the calcitonin receptor (CTR) which for function needs an accessory protein, receptor activity-modifying proteins (RAMPs) 1, 2, or 3. The RAMPs interact to produce different effects via signal transduction and receptor trafficking. Current research has shown that CGRP has a pivotal role in primary headaches while the role of the other peptides or receptors is unclear. The purpose of this paper is to describe their expression in the trigeminal system and to discuss their putative role in migraine.
We observed the peptides CGRP and CT in small- to medium-sized neurons in the trigeminal ganglion (TG), forming immunoreactive C-fibers originating from these neurons. Adrenomedullin was observed in satellite glial cells and fibers, probably processes of the myelinating glial cells in the TG. Amylin was found in the cytoplasm of several TG neurons.
The CGRP receptor (CLR/RAMP1) and the CTR, without a RAMP, were found in the TG, mainly in larger neurons probably forming Aδ-fibers. Furthermore, we observed adrenomedullin receptor AM2 (CLR/RAMP3) mainly in SGCs, the amylin receptor AMY1 (CTR/RAMP1) in neurons, and the AMY3 receptor (CTR/RAMP3) in SGCs.
The wide spectrum of the CGRP family of peptides and receptors in the trigeminal system suggests a role but it is still unclear how this relates to the function of the trigeminovascular system and involvement in the sensory function of the head.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders. 3rd ed. Cephalalgia. 2018;38(1):1–211.
May A. Facial pain is coming home. Cephalalgia. 2020;40(3):227–8.
Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive condition. J Headache Pain. 2019;20(1):117.
Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470–85.
Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies—successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–50.
Edvinsson L. Tracing neural connections to pain pathways with relevance to primary headaches. Cephalalgia. 2011;31(6):737–47.
Hanani M. Satellite glial cells in sensory ganglia: from form to function. Brain Res Brain Res Rev. 2005;48(3):457–76.
Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169(2):683–96.
Warfvinge K, Edvinsson L. Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia. 2019;39(3):342–53.
Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099–142.
Hendrikse ER, Bower RL, Hay DL, Walker CS. Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Cephalalgia. 2019;39:403–19.
Hay DL, Harris PW, Kowalczyk R, Brimble MA, Rathbone DL, Barwell J, et al. Structure-activity relationships of the N-terminus of calcitonin gene-related peptide: key roles of alanine-5 and threonine-6 in receptor activation. Br J Pharmacol. 2014;171(2):415–26.
Hay DL, Poyner DR, Sexton PM. GPCR modulation by RAMPs. Pharmacol Ther. 2006;109(1–2):173–97.
Mallee JJ, Salvatore CA, LeBourdelles B, Oliver KR, Longmore J, Koblan KS, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem. 2002;277(16):14294–8.
McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393(6683):333–9.
Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR review 25. Br J Pharmacol. 2018;175(1):3–17.
Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54(2):233–46.
Edvinsson L, Grell AS, Warfvinge K. Expression of the CGRP family of neuropeptides and their receptors in the trigeminal ganglion. J Mol Neurosci. 2020;70:930–44.
Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett. 1985;62(1):131–6.
Eftekhari S, Gaspar RC, Roberts R, Chen TB, Zeng Z, Villarreal S, et al. Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: a detailed study using in situ hybridization, immunofluorescence, and autoradiography. J Comp Neurol. 2016;524(1):90–118.
Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013;14(11):1289–303.
Blixt FW, Radziwon-Balicka A, Edvinsson L, Warfvinge K. Distribution of CGRP and its receptor components CLR and RAMP1 in the rat retina. Exp Eye Res. 2017;161:124–31.
Miller S, Liu H, Warfvinge K, Shi L, Dovlatyan M, Xu C, et al. Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primate trigeminovascular system using functional antagonist antibodies. Neuroscience. 2016;328:165–83.
Lennerz JK, Ruhle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008;507(3):1277–99.
Copp DH, Cheney B. Calcitonin-a hormone from the parathyroid which lowers the calcium-level of the blood. Nature. 1962;193:381–2.
Findlay DM, Sexton PM. Calcitonin. Growth Factors. 2004;22(4):217–24.
Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab. 1983;57(4):819–24.
Opie EL. On the relation of chronic interstitial pancreatitis to the islands of langerhans and to diabetes melutus. J Exp Med. 1901;5(4):397–428.
Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A. 1987;84(23):8628–32.
Hay DL. Amylin. Headache. 2017;57(Suppl 2):89–96.
Mietlicki-Baase EG, McGrath LE, Koch-Laskowski K, Krawczyk J, Reiner DJ, Pham T, et al. Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior. Neuropharmacology. 2017;123:67–79.
Schultz N, Byman E, Fex M, Wennstrom M. Amylin alters human brain pericyte viability and NG2 expression. J Cereb Blood Flow Metab. 2017;37(4):1470–82.
Young A. Tissue expression and secretion of amylin. Adv Pharmacol. 2005;52:19–45.
Edvinsson L, Goadsby PJ, Uddman R. Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. ScientificWorldJournal. 2001;1:168–80.
Ashina M, Doležil D, Bonner JH, et al. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia: an International Journal of Headache [Cephalalgia]. 2021:41(1):33–44. ISSN: 1468-2982, 2021.
Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192(2):553–60.
Ferrero H, Larrayoz IM, Martisova E, Solas M, Howlett DR, Francis PT, et al. Increased levels of brain adrenomedullin in the neuropathology of Alzheimer’s disease. Mol Neurobiol. 2018;55(6):5177–83.
Ferrero H, Larrayoz IM, Gil-Bea FJ, Martinez A, Ramirez MJ. Adrenomedullin, a novel target for neurodegenerative diseases. Mol Neurobiol. 2018;55:8799–814.
Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, Sakata J, et al. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun. 1994;201(3):1160–6.
Satoh F, Takahashi K, Murakami O, Totsune K, Sone M, Ohneda M, et al. Immunocytochemical localization of adrenomedullin-like immunoreactivity in the human hypothalamus and the adrenal gland. Neurosci Lett. 1996;203(3):207–10.
Serrano J, Uttenthal LO, Martinez A, Fernandez AP, Martinez de Velasco J, Alonso D, et al. Distribution of adrenomedullin-like immunoreactivity in the rat central nervous system by light and electron microscopy. Brain Res. 2000;853(2):245–68.
Juhl L, Petersen KA, Larsen EH, Jansen-Olesen I, Olesen J. The in vivo effect of adrenomedullin on rat dural and pial arteries. Eur J Pharmacol. 2006;538(1–3):101–7.
Ashina M, Hansen JM, Dunga BOA, Olesen J. Human models of migraine—short-term pain for long-term gain. Nat Rev Neurol. 2017;13(12):713–24.
Petersen KA, Birk S, Kitamura K, Olesen J. Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. Cephalalgia. 2009;29(1):23–30.
Edvinsson JCA, Warfvinge K, Krause DN, Blixt FW, Sheykhzade M, Edvinsson L, et al. C-fibers may modulate adjacent Adelta-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. J Headache Pain. 2019;20(1):105.
May A, Burstein R. Hypothalamic regulation of headache and migraine. Cephalalgia. 2019;39(13):1710–9.
May A. Understanding migraine as a cycling brain syndrome: reviewing the evidence from functional imaging. Neurol Sci. 2017;38(Suppl 1):125–30.
Schulte LH, May A. Of generators, networks and migraine attacks. Curr Opin Neurol. 2017;30(3):241–5.
Lundblad C, Haanes KA, Grande G, Edvinsson L. Experimental inflammation following dural application of complete Freund’s adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage. J Headache Pain. 2015;16:91.
Noseda R, Schain AJ, Melo-Carrillo A, Tien J, Stratton J, Mai F, et al. Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Cephalalgia. 2020;40(3):229–40.
Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158(4):543–59.
Walker CS, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson L, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol. 2015;2(6):595–608.
Hoare SR. Mechanisms of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors. Drug Discov Today. 2005;10(6):417–27.
Hay DL, Pioszak AA. Receptor activity-modifying proteins (RAMPs): new insights and roles. Annu Rev Pharmacol Toxicol. 2016;56:469–87.
Bower RL, Hay DL. Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development. Br J Pharmacol. 2016;173(12):1883–98.
Lin HY, Harris TL, Flannery MS, Aruffo A, Kaji EH, Gorn A, et al. Expression cloning and characterization of a porcine renal calcitonin receptor. Trans Assoc Am Phys. 1991;104:265–72.
Njuki F, Nicholl CG, Howard A, Mak JC, Barnes PJ, Girgis SI, et al. A new calcitonin-receptor-like sequence in rat pulmonary blood vessels. Clin Sci (Lond). 1993;85(4):385–8.
Naot D, Cornish J. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone. 2008;43(5):813–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Edvinsson, L., Warfvinge, K. (2021). The CGRP Family of Neuropeptides and their Receptors in the Trigeminovascular System. In: Maassen van den Brink, A., Martelletti, P. (eds) Monoclonal Antibodies in Headache . Headache. Springer, Cham. https://doi.org/10.1007/978-3-030-69032-8_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-69032-8_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-69031-1
Online ISBN: 978-3-030-69032-8
eBook Packages: MedicineMedicine (R0)